Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 8/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | FUT6 | P51993 | 2/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19662514 | 1.00 | POLB (0.46) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL19662810 | 0.89 | P2RX3 (0.44) | POLBP2RY2 | |
| SCHEMBL19662411 | 0.89 | P2RX3 (0.44) | POLBP2RY2 | |
| SCHEMBL21786894 | 0.88 | POLB (0.47) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL21786898 | 0.88 | POLB (0.47) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL24913296 | 0.87 | POLB (0.51) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL21786987 | 0.85 | POLG (0.44) | POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL24913270 | 0.85 | POLG (0.44) | POLBP2RY2P2RY4P2RY6 | |
| SCHEMBL24913468 | 0.85 | POLB (0.49) | POLB | |
| SCHEMBL24913325 | 0.85 | POLB (0.49) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | POLB 11/4885P2RY2 1489/4885P2RY4 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.